Salute e Benessere
Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight
Vedolizumab is a biologic medication approved for both intravenous (IV) and subcutaneous (SC) use, with regulatory approvals varying by region. The SC formulation is authorized for use in the United States , European Union, and over 50 other countries, while the IV formulation has received approval in more than 70 countries, including the US and the EU. Collectively, vedolizumab IV and SC have accumulated over one million patient-years of global exposure.
Vedolizumab is a humanized monoclonal antibody that selectively targets the alpha4beta7 integrin, blocking its interaction with mucosal addressin cell adhesion molecule 1 (MAdCAM-1) — a protein primarily found on blood vessels and lymph nodes in the gastrointestinal tract. This integrin is present on certain white blood cells involved in the inflammatory processes of ulcerative colitis and Crohn's disease. By disrupting the binding between alpha4beta7 integrin and MAdCAM-1, vedolizumab may reduce the migration of these immune cells into the gut, thereby decreasing inflammation.
For adults with ulcerative colitis, the advised dosage of ENTYVIO is 300 mg given through intravenous infusion at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks. Treatment should be discontinued if no clinical improvement is observed by week 14.
Learn more about ENTYVIO projected market size for Crohn's disease and ulcerative colitis @
Crohn's disease is a progressive type of inflammatory bowel disease (IBD) that results in chronic inflammation throughout the gastrointestinal tract, most commonly affecting the terminal ileum and colon. This inflammation can lead to complications such as strictures, fistulas, and ulcers. In 2024, there were diagnosed prevalent cases of Crohn's disease in the United States .
Current treatment approaches primarily include biologics such as (HUMIRA and its biosimilars), (STELARA), (REMICADE and biosimilars), along with , and other therapies. Among these, adalimumab held the largest market share in the 7MM in 2024, generating around in revenue for Crohn's disease treatment.
In 2024, the market size of Crohn's disease was highest in the US among the 7MM, accounting for approximately , which is further expected to increase at a . The Crohn's disease market is projected to expand due to the introduction of novel therapies with improved efficacy and more convenient routes of administration, broader use of biologics in pediatric populations, growing commercial opportunities in biologic-treated patients, advancements in biomarker development for early diagnosis, and the overall rising prevalence of the disease.
Discover more about the Crohn's disease market in detail @
Ulcerative colitis is one of the primary types of chronic inflammatory bowel disease (IBD) affecting the gastrointestinal tract. It is an idiopathic and long-standing inflammation of the colonic mucosa, typically presenting with symptoms like diarrhea, abdominal discomfort, and rectal bleeding. In 2023, there were an estimated diagnosed prevalent cases of ulcerative colitis across the 7MM, with numbers expected to rise over the forecast period.
According to current US treatment guidelines, mild-to-moderate cases are initially managed with aminosalicylates or by using corticosteroids for induction followed by maintenance therapy with aminosalicylates. For patients with moderate-to-severe disease, maintenance treatment may involve immunosuppressants like azathioprine or 6-mercaptopurine after corticosteroid induction. Alternatively, biologics—particularly anti-TNF agents such as infliximab or adalimumab—can be used alone or alongside immunosuppressants to achieve and sustain remission and mucosal healing.
The treatment landscape across the 7MM is categorized into commonly used drug classes, including conventional therapies, , and others, reflecting some variations in prescribing practices.
Looking ahead, the anticipated introduction of novel therapies, increased focus on early detection, enhanced use in secondary care, improved implementation strategies, and growing disease awareness are likely to contribute to more effective management of ulcerative colitis. As a result, the ulcerative colitis market will grow from in 2023 at a significant CAGR by 2034. However, the high costs of new treatments and the financial burden of disease complications may pose challenges to widespread adoption.
For a comprehensive view of the ulcerative colitis market, check out the
Despite the presence of biosimilars, innovation in Crohn's disease and ulcerative colitis treatment remains strong, with several emerging therapies exploring new inflammatory pathways to improve efficacy and long-term outcomes. , a combination macrolide antibiotic, is in Phase III trials targeting potential mycobacterial involvement. , an S1P receptor modulator, works by limiting lymphocyte migration and reducing inflammation. , which inhibits IL-23, is under evaluation for its immune-modulating effects, while , a TNF inhibitor conjugated with a steroid, aims to enhance TNF suppression.
Additional pipeline therapies include in Phase III and in Phase II. are also developing , a monoclonal antibody targeting TNFSF15. These investigational drugs represent significant progress for patients unresponsive to current treatments.
A range of other promising candidates are in development, each targeting unique pathways. is in Phase II and acts via LANCL2, while from is also in Phase II. is being studied for its ability to upregulate miR-124. , an anti-TL1A antibody, is in Phase II trials, and , a mesenchymal stem cell therapy, is progressing in Phase III, offering regenerative potential.
Other noteworthy agents in Phase II include from , a TYK2 inhibitor; from , targeting CCR9; , which blocks TNFR1 signaling; from , targeting ALK5/TGFβR1; by , a PPARγ partial agonist; and by , an α4β7 integrin inhibitor. Together, these developments illustrate a robust and diversified IBD pipeline.
To know more about the number of competing drugs in development, visit @
Discover how ENTYVIO is shaping the Crohn's disease and ulcerative colitis treatment landscape @
ENTYVIO has established itself as a in the treatment of moderate to severe ulcerative colitis and Crohn's disease. As a gut-selective integrin antagonist, ENTYVIO offers a differentiated mechanism of action compared to , which contributes to its positioning as a safer long-term option, particularly for patients at risk of systemic immunosuppression. Its in inducing and maintaining remission have led to its widespread adoption, particularly among patients who have failed previous therapies.
The biologics market for inflammatory bowel disease is , with key players including , and newer entrants like . ENTYVIO has managed to capture by appealing to both gastroenterologists and patients seeking gut-targeted treatment. Its , though initially a barrier, has been partially offset by the 2019 launch of the in global markets, enhancing patient convenience and adherence. However, uptake in the US for the SC version has been slower due to regulatory timelines and physician inertia.
is also a factor shaping ENTYVIO's future market dynamics. While biosimilars of anti-TNFs are gaining traction, ENTYVIO currently remains insulated due to , with . This provides Takeda a limited window to maximize revenue, expand its patient base, and reinforce brand loyalty. Strategic moves such as will be crucial to maintaining its competitive edge.
Moreover, the shift in are increasingly influencing biologic prescribing behavior. Takeda must continue to demonstrate value through outcome-based contracts and cost-effectiveness data. As newer agents with novel mechanisms enter the market, maintaining differentiation and proving long-term value will be central to ENTYVIO's sustained success.
Dive deeper to get more insight into ENTYVIO's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Crohn's disease companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Ulcerative Colitis companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Ulcerative Colitis companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/takedas-entyvio-continues-growth-trajectory-in-ulcerative-colitis-and-crohns-disease--delveinsight-302428443.html